BMAL1 and glioblastoma: Due to the positive significant correlation between an altered clock i.e., increased levels of BMAL1 in GBM, and VEGF levels54 future studies may combine a VEGF inhibitor such as bevacizumab with a clock manipulator such as a CRY or REV-ERB agonist.